TAK
TAKEDA PHARMACEUTICAL CO LTD
Next earnings Jul 28, 2026 · consensus $53.06 EPS, $1.17T rev
$16.77
▲ +4.94%$16.77▲ +15.45%
over 1Y
L $13.01H $18.77
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+4.9%
1W+7.2%
1M+10.5%
3M-10.5%
YTD+9.1%
1Y+15.4%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 19 analysts
Buy
Mixed signals in the latest filings.
TAKEDA PHARMACEUTICAL CO LTD shows limited reported revenue.
On these fundamentals, TAK screens as SELL on the SEC figures.
Rule-based analysis, generated automatically from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 4, 2026, 10:18 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Financials · annual, by fiscal year
No income data filed.
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$53.0B
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield—
FCF yield—
Quality & risk
ROIC (est.)—
Free cash flow—
Total debt—
Net cash—
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY-0.5%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Recent filings
all on EDGAR ↗6-KPeriod ending 2026-06-292026-06-29open ↗6-KPeriod ending 2026-06-262026-06-26open ↗6-KPeriod ending 2026-06-242026-06-24open ↗6-KPeriod ending 2026-06-242026-06-24open ↗6-KPeriod ending 2026-06-242026-06-24open ↗IRANNOTICEFiling2026-06-17open ↗20-FPeriod ending 2026-03-312026-06-17open ↗6-KPeriod ending 2026-06-092026-06-09open ↗6-KPeriod ending 2026-06-052026-06-05open ↗6-KPeriod ending 2026-06-052026-06-05open ↗6-KPeriod ending 2026-06-012026-06-01open ↗6-KPeriod ending 2026-05-262026-05-26open ↗
Frequently asked
- Is TAKEDA PHARMACEUTICAL CO LTD (TAK) a buy?
- TAK currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Mixed signals in the latest filings.
- What is TAKEDA PHARMACEUTICAL CO LTD's quality score?
- TAK scores 70.62123345634441/100 (grade B) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001395064, latest 6-K filed 2026-06-29) · EODHD · as of 7/4/2026, 2:18:43 PM.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.